Alert: New Earnings Report (11/2/23)-Regeneron Pharmaceuticals Inc (NASDAQ: REGN).
For its third fiscal quarter (ending September 30), Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has reported a -23% decline in E.P.S. from $12.31 a year ago to $9.48 in the current quarter. This performance was $-1.36 […]